Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bioretec Ltd’s Annual Report and Financial Statements 2022 are published

Bioretec Ltd                       Company announcement      17 March 2023 at 3:15 p.m. EETBioretec Ltd has today published its 2022 Annual Report, Report by the Board of Directors, and Financial Statements. The publications are attached to this release and also available in Finnish and English on the company’s website at www.bioretec.com/investors/investors-in-english/reports-and-presentations. Further inquiries: Timo Lehtonen, CEO, +358 50 433 8493Johanna Salko, CFO, +358 40 754 8172  Certified advisor: Nordic Certified Adviser AB, +46 70 551 67 29 Information about

Audientes A/S – update of financial calendar for 2023

Company announcement no. 06-2023March 17, 2023 Audientes A/S (CVR 36047631) is announcing an update in its financial calender for 2023 to align activities and allow some members of the recently appointed Board of Directors to develop an informed view of the company, risk management and corporate governance matters prior to completion and approval of the Annual Report for 2022.First, the publication date of the Annual Report for 2022 is now moved from 23 March, 2023 to 13 April, 2023, to allow some members of the recently appointed Board of Directors sufficient time to review and

Stayble Therapeutics AB publishes prospectus relating to the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NB: This is an English convenience translation of this press release. In case of any discrepancy, the

Trading Update and New Funding

Following an assessment of preliminary results for the first two months of Q1 2023 and updated forecast numbers for Q1 and Q2, Ayima Group has determined it is necessary to make an announcement regarding current trading conditions. The first two months of the quarter have seen a significant reduction in profitability, due to extraordinary delays in routine contract renewals for long-term clients and some client terminations. Several clients affected have quoted unease about macroeconomic conditions such as inflation and downturns in the tech industry and have been reluctant to commit

Wicket Gaming´s Board of Directors has decided on a directed issue of units to underwriters in connection with the completed rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.  Wicket Gaming AB ("Wicket Gaming" or the "Company") has, as previously announced, completed the rights issue of units which the extraordinary general meeting decided on January 4, 2023 (the "Rights Issue"). In accordance with the underwriting agreements, Wicket Gaming'

Eevia Health Plc receives a 146 KSEK / 13 KEUR sales order for a bilberry extract

Eevia Health Plc, (”Eevia” or ”The Company”), has received sales order from Taiwan of c. 13 KEUR for an organically certified bilberry extract.The Taiwanese customer is an important and competitive distributor of ingredients and nutritional supplements in Taiwan. The distributor has a professional approach to quality and a strong presence in the market. The sales value to Eevia of this new order is c. KEUR 13 EUR. The product is Eevia’s branded ingredient Feno-Myrtillus® 25 Organic, which is a highly concentrated and organically certified bilberry extract with 25% anthocyanins. There

Fetch.ai Surges 550% as CEO Reveals How its Tech Will Create New Economy

Friday March 17th 2023 – Humayun Sheikh, CEO of AI-based blockchain project Fetch.ai, spoke exclusively to Cryptonews  about how a new AI bot framework – Autonomous Economic Agent (AEA) – will create a new economy. The interview, conducted by cryptonews.com reporter Sam Cooling, comes after Fetch.ai saw its token, $FET, surge by 550% in February – coinciding with an increase in interest in AI technology following the rise of ChatGPT and Google Bard. Sheikh explains why he believes the AEA framework will drive ecosystem growth by enabling the deployment

Scandinavian ChemoTech participates and presents at the LSI Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and CEO Mohan Frick will present the company's tumor-specific electroporation (TSE) at the LSI Emerging Medtech Summit 2023 in California, USA. The event brings together the medtech industry's top strategists, investors and innovators.The conference is an event where ChemoTech and other medical device companies will present their innovations to some of the biggest players and investors in the medtech field. Participants include Medtronic, Johnson & Johnson and Boston Scientific as well as representatives from institutional investors and Family Offices. The event is

Communicate scan results and impress your patients with Planmeca Imprex™

Planmeca is introducing a mobile scanning station to support dental professionals in intraoral scanning and patient communication. Designed to fit any clinical setup, the Planmeca Imprex™ scanning station for Planmeca Emerald® S intraoral scanner ensures ergonomic working positions and allows visualising the oral health conditions and treatment plans to patients. Planmeca Imprex™ mobile scanning station allows dental professionals to impress their patients with high-quality digital impressions. The portable scanning station with a 15’’ touch screen can be moved freely close to any

Platzer’s Annual Report 2022 in English

Platzer’s Annual Report 2022 in English is now published on our website platzer.se , where it can also be downloaded.The Annual General Meeting of Platzer Fastigheter Holding AB (publ) will take place on Thursday, 23 March, 2023. Platzer Fastigheter Holding AB (publ) For further information please contact:P-G Persson, CEO, Platzer, tel:  +46(0)734-11 12 22Fredrik Sjudin, CFO, Platzer, tel: +46(0)721-27 77 78 This information is information that Platzer Fastigheter Holding AB (publ) is obliged to make public pursuant to the

Immunovia publishes prospectus relating to the rights issue

NOT FOR PUBLICATION, RELEASE DISSEMINATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SWITZERLAND, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER STATE, TERRITORY OR JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN IMMUNOVIA AB (PUBL). FOR MORE INFORMATION, SEE THE SECTION IMPORTANT INFORMATION BELOW.LUND, SWEDEN – Immunovia AB (publ) ("

Vianode selected as candidate for EU IPCEI grant

Vianode has been selected as one of five Norwegian candidates for an EU IPCEI grant, following the government’s and Minister of Trade and Industry Jan Christian Vestre’s decision to enroll Norway in IPCEI EuBatIn.Vianode builds industrial leadership in advanced battery materials, by producing sustainable anode materials with significantly lower emissions compared to conventional production. To succeed in building industry leadership in advanced battery materials, the company depends on competitive framework conditions. The Norwegian participation in IPCEI EUBatIn represents a major step

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release March 17, 2023 at 1:30 p.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on March 16, 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total holding in Nokian Tyres shares and voting rights owned by the funds and accounts managed by JPMorgan Chase & Co. fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on March 15, 2023. Total positions of person(s) subject to the notification obligation: +---

Offline payment security – new webinar by Crunchfish in partnership with Lipis Advisors

Offline payment security was the topic of the webinar in the series Enabling offline payments in an online world to discuss the 2nd white paper – A practical guide for offline payment security that Lipis Advisors have released in partnership with Crunchfish. A panel discussion with participation from Lipis Advisors, V-key and Crunchfish followed a presentation of the white paper.    The recording of the webinar discussing the 2nd whitepaper 

Isofols appoints Roy Jonebrant as new acting Chief Financial Officer

Gothenburg, Sweden, March 17, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roy Jonebrant has been appointed as the new acting Chief Financial Officer. He succeeds Gustaf Albèrt who is leaving the role as CFO, which was announced at the end of 2022.Roy works as an interim consultant and has experience working as a CFO and financial manager in both unlisted and listed environments. He has solid experience from various leading positions in finance, accounting and business development and the last 15 years preferably with the various needs of listed

Interesting innovations at Feminvest’s annual event

On International Women’s Day, Feminvest held its annual event FEARLESS. BioStock had the opportunity to attend the event, where speakers, panels, investors and life science entrepreneurs participated. We summarize the event’s message and highlight participating companies in medtech and digital health.Read the article at biostock.se: https://www.biostock.se/en/2023/03/interesting-innovations-at-feminvests-annual-event/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

WntResearch attends the BIO-Europe partnering conference in Basel March 20-22

BIO-Europe is a partnering conference in the life science industry that enables meetings with potential partners. WntResearch CCO Klaus Christensen will attend to present the drug candidate Foxy-5 and its potential.The networking event takes place with physical presence on site in Basel, Switzerland, 20-22 March and is expected to bring together over 2,800 senior executives from around the world to participate in more than 15,000 individual meetings. The event is followed by a digital on 28-30 March in which Klaus Christensen also will attend. "This is the first time BIO-Europe Spring is

Vår Energi ASA: Notification of trade by primary insider

Sandnes, Norway, 17 March 2023: Senior Vice President Commercial, Ove André Årdal in Vår Energi has bought 6 000 shares in the company at a price of NOK 26.5424. This information is subject to the disclosure requirements pursuant to MAR article 19 and Section 5-12 the Norwegian Securities Trading Act. Contact Investor relations Ida Marie Fjellheim, Head of Investor Relations +47 90509291 ida.fjellheim@varenergi.no About Vår Energi Vår Energi is a leading independent upstream oil and gas company on the Norwegian continental shelf (NCS). We are committed to deliver a

Nordea completes third share buy-back programme

Nordea Bank AbpStock exchange release – Other information disclosed according to the rules of the Exchange17 March 2023 at 13.00 EET Nordea has now completed its third share buy-back programme announced in July 2022. From 20 July 2022 to 16 March 2023, Nordea repurchased 150,069,276 of its own shares (FI4000297767) at an average price per share of EUR 9.99. On 18 July 2022 Nordea announced a share buy-back of up to EUR 1.5bn, based on the authorisation granted by the Annual General Meeting 2022. The purpose of share buy-backs is to pursue an efficient capital structure and

Vestas secures 50 MW order in Germany for wind project that will provide energy for green hydrogen production

News release from Vestas Northern and Central EuropeHamburg, 17 March 2023 Vestas has received a 50 MW order from Energiepark Bad Lauchstädt GmbH to power the Bad Lauchstädt TerraWatt project in Saxony-Anhalt, Germany. The order includes supply, installation, and commissioning of eight V162-6.2 MW turbines at a hub height of 169m, as well as a 25-year Active Output Management 5000 (AOM 5000) service agreement designed to ensure optimised performance of the asset. Energiepark Bad Lauchstädt will use the wind energy to produce green hydrogen at an industrial scale, thanks to a large

CEO Pernilla Sandwall invited to present Foxy-5 at scientific workshop on Wnt signalling in Heidelberg on 17 March

Six researchers and two pharmaceutical company representatives active in Wnt signalling will be speakers, including Pernilla Sandwall.Wnt is the name of a large family of signalling proteins that control and effect a large number of processes in the cell. Unlike hormones and several growth factors, Wnt proteins act primarily in the cell's immediate vicinity through local signalling between adjacent cells. Wnt signals are active in many different contexts, both during early development and in the regulation of normal tissue functions. Of particular interest at this workshop is that several

Genetic Analysis presents at Mangold Insight’s Investor Day

OSLO, NORWAY, March 17, 2023 – Genetic Analysis (“GA”) will attend Mangold Insight’s Investor Day next Wednesday, 22 March 2023. Ronny Hermansen, CEO, and Kari Furu, Head of Product and Business Development, will present the company, the booming microbiome market, and the global potential and recognition of the GA-map® platform.On March 22, GA has been invited to attend and present the company at Mangold Insight’s Investor Day. The presentation will be live-streamed on Mangold Insights website

Carbonhand achieves regulatory approval in Australia

Carbonhand has been approved for sales in Australia after achieving Australian regulatory approval with listing on the Australian Register of Therapeutic Goods from 1 March 2023. With the approval, Bioservo's Australian distributor has started the sales process and has already initiated the prescription process to the first patients.[Carbonhand hjlper till i vardagen] The Australian market has several generous reimbursement schemes for people in need of assistive devices. In addition to the national compensation system NDIS (National Disability Insurance Scheme) for people with

There are no items matching the current filter
There are no more items matching the current filter
Back to top